Epidermal Growth Factor Receptor Inhibitor Database
|
|
|
|
|
|
|
|
|
|
|
| Experimental Information | |
| Enzymatic Activity | |
| Molecule Id | EGIN0000003 |
| PMID | 21080629 |
| Assay Used | Kinase and Cellular proliferation assay |
| Experimently Validated | Yes |
| EGFR (IC50) | 2.9 nM |
| HER2 (IC50) | 4.5 nM |
| HER4 (IC50) | - |
| Mutant L858R (IC50) | - |
| Mutant T790M (IC50) | - |
| Double Mutant (IC50) | - |
| Average ERBB2 and ERBB1 (IC50) | - |
| Inhibition EGFR (%) | - |
| Inhibitory Concentration | - |
| Inhibition HER2 (%) | - |
| Inhibitory Concentration | - |
| Ki (EGFR) | - |
| Ki (HER2) | - |
| Ki (HER4) | - |
| Kd (EGFR) | - |
| Kd (L858R) | - |
| Kd (T790M) | - |
| Kd (L858R/T790M) | - |
| Kd (Other mutation) | - |
| Note | The paper describes the Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2),and Histone Deacetylase Activity |
| Extra | - |
| Cellular Activity | ||||||||||||||
| S.No. | Cell Line | Desp. | IC50 | IC80 | ED50 | GI50 | GI90 | EC50 | Kd | Inhibition (%) | Inhibitory Conc. | |||
| 1 | A431 | - | 970 nM | - | - | - | - | - | - | - | - | |||
| 2 | A549 | - | 8500 nM | - | - | - | - | - | - | - | - | |||
| 3 | Cal27 | - | 7 nM | - | - | - | - | - | - | - | - | |||
| 4 | HeLa | - | 5900 nM | - | - | - | - | - | - | - | - | |||
| 5 | SKBR3 | - | 2 nM | - | - | - | - | - | - | - | - | |||
| 6 | SKOV3 | - | 3 nM | - | - | - | - | - | - | - | - | |||
| Activity against Receptor | |
| EGFR | Yes |
| HER2 | Yes |
| HER4 | - |
| Wild type | Yes |
| Mutant | - |
| Inhibitor Binding | |
| EGFR | - |
| HER2 | - |
| HER4 | - |